PFIZER said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday.

The tariff threat come just a few days after the White House sent letters to major drugmakers demanding slashed prices for US ...

Shares in the data-software company were up 7.8% Tuesday after it posted higher quarterly results and [boosted its annual ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

Second Quarter 2025 Results Key Financial Results Revenue: US$14.7b (up 10% from 2Q 2024).

DAX rallies as Chinese exports, Fed rate cut bets, and upbeat German trade data lift sentiment. Investors eye US jobs data ...

XAU/USD consolidates above the 50-day MA, as softer U.S. data boosts rate cut odds. Gold price future hinges on inflation and ...

Trump has said that tariffs on pharmaceutical imports could reach 250%, the steepest rate he has proposed for the sector. Trump, who in July threatened 200% duties, wants to motivate drug companies to ...

The issuer is solely responsible for the content of this announcement.

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

New data highlights an unprecedented crisis in National Health Service patient waiting lists and sheds light on how the ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...